Abstract
The fungal natural product aspergillomarasmine A (AMA) is an inhibitor of metallo‐β‐lactamases and a promising co‐drug candidate for reversing bacterial β‐lactam resistance. The biosynthesis of AMA from L‐Asp and O‐phospho‐L‐serine is catalyzed by AMA synthase, which possesses high synthetic potential for the biocatalytic preparation of AMA and related aminopolycarboxylic acids. Here, we identified and structurally characterized an AMA synthase from Pyrenophora teres f. teres 0‐1 (PteAMAS). Crystallographic analysis revealed a unique homotetrameric fold and a highly hydrophilic active site, which supports the PLP‐dependent β‐replacement catalytic mechanism. Furthermore, we demonstrated the utility of PteAMAS for the biocatalytic synthesis of AMA and its analogues, achieving structural diversification of the APA1 moiety through a modular two‐enzyme system involving PteAMAS and a selective C‐N lyase, namely EDDS lyase or 3‐methylaspartate ammonia lyase variant MAL‐Q73A. In addition, we exhibited the usefulness of PteAMAS for convenient synthesis of various S‐alkyl, ‐aryl, and ‐arylalkyl substituted L‐cysteines, which are valuable non‐canonical amino acids with broad pharmaceutical applications. The present study has not only provided the structural basis for catalysis and substrate recognition by PteAMAS, but also paved the way for biocatalytic preparation of structurally complex AMA analogues and various non‐canonical amino acids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.